NEW YORK (GenomeWeb News) – BioMarker Strategies has raised $1.7 million through a private funding round that included the Abell Foundation, the Baltimore-based company said today.

BioMarker Strategies is developing a tumor biopsy processing and testing system called SnapPath that is intended to quickly analyze a solid sample at the point of biopsy. It also is developing a series of pathway-based, ex-vivo biomarker tests to help physicians make therapeutic decisions for cancer patients.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.

Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.

In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.